Therapeutic drug monitoring in solid-organ transplant recipients
- 1 December 2000
- journal article
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 5 (4) , 330-335
- https://doi.org/10.1097/00075200-200012000-00006
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- CLINICAL BENEFIT OF NEORAL DOSE MONITORING WITH CYCLOSPORINE 2-HR POST-DOSE LEVELS COMPARED WITH TROUGH LEVELS IN STABLE HEART TRANSPLANT PATIENTS1Transplantation, 1999
- Renal insufficiency after heart transplantation: a case-control studyNephrology Dialysis Transplantation, 1998
- Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine*Clinical Pharmacology & Therapeutics, 1997
- A RANDOMIZED, PROSPECTIVE MULTICENTER PHARMACOEPIDEMIOLOGIC STUDY OF CYCLOSPORINE MICROEMULSION IN STABLE RENAL GRAFT RECIPIENTS1,2,3Transplantation, 1996
- Quality Assessment Issues of New Immunosuppressive Drugs and Experimental ExperienceTherapeutic Drug Monitoring, 1996
- Pharmacokinetics and Therapeutic Drug Monitoring of ImmunosuppressantsTherapeutic Drug Monitoring, 1995
- Monitoring of TPMT in Heart Transplant Recipients under Immunosuppressive Therapy with AzathioprineArtificial Organs, 1995
- CALCINEURIN ACTIVITY IS ONLY PARTIALLY INHIBITED IN LEUKOCYTES OF CYCLOSPORINE-TREATED PATIENTSTransplantation, 1995
- CYCLOSPORINE TROUGH LEVELS, ACUTE REJECTION, AND RENAL DYSFUNCTION AFTER HEART TRANSPLANTATIONTransplantation, 1995
- Cyclosporine monitoring.Clinical Chemistry, 1989